BioSpace News Archive

Rockwell Medical, Inc. provided a business update, financial results for the second quarter ended June 30, 2018 and announced the restatement of its financial results for the first quarter ended March 31, 2018.

U.S. Court of Appeals Denies Petitions for Panel Rehearing and Rehearing En Banc

ContraFect Corporation announced that Cara Cassino, M.D., the Company’s Executive Vice President of Research and Development and Chief Medical Officer, has been invited by the Food and Drug Administration (FDA) to participate in a panel discussion for a public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections”.

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients.

Taiwan Liposome Company, Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of medical needs in pain management, ophthalmology, and oncology, today announced the dosing of the first patients in a Phase I/II trial for TLC590.

Uni-flo2 Single-nasal Cannula System (Uni-flo2), a breakthrough patient-centric solution that ensures continuous oxygen flow equivalent to the low flow dual-pronged cannula but with half the skin contact, announces the release of its white paper, “Breathe Easier: Single-Prong Cannula Represents Important Breakthrough in Oxygen Therapy for COPD Patients.”

Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities.

GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that David A. Dodd has been appointed President and Chief Executive Officer, effective September 1, succeeding Robert McNally, PhD, who has announced his retirement.

Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen)

CVS Health (NYSE: CVS) is actively working with its Ohio Managed Medicaid clients to restructure its contracts to implement the Ohio Department of Medicaid’s new “pass-through” pricing model requirement, effective January 1, 2019.